Key Takeaways
- Q1 revenue climbed 6.2% year-over-year to $1.024B, but COO shares dropped 2.17%.
- Adjusted EPS surged 20% to $1.10; company lifts full-year outlook.
- CooperVision segment expands 7.6% on MyDay and MiSight momentum.
- Asia-Pacific region declines 4% due to legacy hydrogel product softness.
- CooperSurgical gains 3.3% while free cash flow reaches $159M.
Shares of The Cooper Companies, Inc. (COO) experienced downward pressure despite delivering impressive fiscal first-quarter results that exceeded expectations. The stock ended trading at $80.20, down 2.17%, before extending losses to $75.23 in pre-market activity. This retreat came even as the medical device manufacturer reported accelerating earnings momentum and enhanced full-year projections.
The Cooper Companies, Inc., COO
Revenue acceleration and profitability gains highlight quarterly results
For its fiscal first quarter, company posted consolidated revenue totaling $1.024 billion. This represented a 6.2% increase versus the year-ago period. On an organic basis, revenue expanded 2.9%, demonstrating consistent momentum in core business operations.
Profitability metrics showed meaningful improvement throughout the quarter. The non-GAAP gross margin climbed to 68.1%, while the operating margin reached 26.9%. Strategic cost management initiatives and restructuring savings enabled operating expenses to shrink as a percentage of total revenue.
Adjusted earnings per share jumped 20% to $1.10 for the quarter. The company maintained approximately 197 million weighted average shares outstanding during the period. Reflecting confidence in ongoing business trends, management elevated its full-year non-GAAP EPS forecast to a range of $4.58 to $4.66.
Premium contact lens portfolio powers CooperVision expansion
The CooperVision division generated $695 million in quarterly sales, representing 7.6% growth compared to last year. Organic revenue within the segment advanced 3.3%, supported by sustained worldwide demand for contact lens products. Strategic product launches and geographic penetration fueled the unit’s outperformance.
Increased penetration of MyDay premium contact lenses drove significant adoption gains in multiple overseas territories. Meanwhile, MiSight lenses maintained strong traction within the growing myopia control category. MiSight sales climbed 23% year-over-year to reach $28 million.
The Asia-Pacific territory, however, experienced a 4% revenue contraction during the period. The decline stemmed primarily from continued weakness in older-generation hydrogel products sold in Japan. Company executives anticipate this softness will persist through the second quarter before growth resumes in the third quarter.
CooperSurgical demonstrates recovery momentum and robust cash flow
CooperSurgical posted quarterly sales of $329 million, reflecting 3.3% year-over-year improvement. Organic growth measured 2.2%, signaling progressive strengthening across the medical device product lineup. Fertility-related products exhibited early indications of demand normalization.
The fertility category delivered $127 million in quarterly revenue and expanded 3% organically. Strengthening procedure volumes and reliable product ordering patterns contributed to the segment’s performance. These results underscore gradual recovery trends within the reproductive medicine marketplace.
During the quarter, the company produced $159 million in free cash flow. Capital deployment activities included repurchasing 1.1 million shares for $92 million and refinancing $950 million in term debt, extending maturity to February 2031. Net debt decreased to roughly $2.4 billion as the balance sheet strengthened.
Executive leadership remains committed to capturing market share, enhancing operational performance, and maintaining prudent capital deployment practices. These strategic priorities underpin sustained growth prospects across both primary business segments. Nevertheless, shares retreated following the earnings announcement and continued declining in subsequent trading sessions.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
